First experiences with an accelerated CMV antigenemia test: CMV Brite Turbo assay.
BACKGROUND
Cytomegalovirus disease is still a major problem in immunocompromised patients, such as bone marrow or kidney transplantation patients. The detection of viral antigen in leukocytes (antigenemia) has proven to be a clinically relevant marker of CMV activity and has found widespread application. Because most existing assays are rather time-consuming and laborious, an accelerated version (Brite Turbo) of an existing method (Brite) has been developed. The major modification is in the direct lysis of erythrocytes instead of separation by sedimentation.


OBJECTIVE
In this study the Brite Turbo method has been compared with the conventional Brite method to detect CMV antigen pp65 in peripheral blood leukocytes of 107 consecutive immunocompromised patients.


RESULTS
Both tests produced similar results. Discrepancies were limited to the lowest positive range and sensitivity and specificity were comparable for both tests.


CONCLUSIONS
Two major advantages of the Brite Turbo method could be observed in comparison to the original method: assay-time was reduced by more than 50% and only 2 ml of blood was required. An additional advantage was the higher number of positive nuclei in the Brite Turbo method attributable to the increased number of granulocytes in the assay. Early detection of CMV infection or reactivation has become faster and easier with this modified assay.
Visser
C E
CE
Department of Virology, Leiden University Medical Centre, PO Box 9600, 2300 RC, Leiden, The Netherlands. visser@virology.azl.nl
van Zeijl
C J
CJ
de Klerk
E P
EP
Schillizi
B M
BM
Beersma
M F
MF
Kroes
A C
AC
D003587:Cytomegalovirus / Q000276:immunology / Q000302:isolation & purification*; D003586:Cytomegalovirus Infections / Q000175:diagnosis* / Q000276:immunology / Q000821:virology; D006801:Humans; D016867:Immunocompromised Host; D010750:Phosphoproteins / Q000097:blood*; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D014180:Transplantation / Q000009:adverse effects; D014763:Viral Matrix Proteins / Q000097:blood*; D014766:Viremia / Q000175:diagnosis / Q000821:virology
D010750:Phosphoproteins; D011933:Reagent Kits, Diagnostic; D014763:Viral Matrix Proteins; C065418:cytomegalovirus matrix protein 65kDa